GONZALES, Texas, March 17, 2026 /PRNewswire/ -- As the U.S. cattle herd falls to a 75-year low and beef prices climb to record highs, Texas ranchers are under growing pressure to protect every acre of usable pasture. Yet invasive brush continues to spread, and conventional control methods often prove too costly, too imprecise or too limited by terrain. Agricultural drones are changing that equation, offering a more practical way to deliver herbicide treatments in dense brush and hard-to-reach areas without damaging the soil or grass underneath.
When the Brush Takes Over
That challenge is creating growing demand for brush control specialists like Curtis Schramm, owner of Texas Agridrone Services. He operates in Gonzales County, a Texas cattle region where livestock accounts for 93 percent of agricultural sales and crop rows make up just 10 percent of farmland. There, brush encroachment is visible and relentless. According to Texas A&M research, a single adult mesquite tree can consume up to 20 gallons of water per day during peak growing season, while prickly pear density can increase 25 to 30 percent each year during prolonged drought. In a region that depends almost entirely on rainfall, that kind of pressure steadily shrinks the amount of usable pasture available to ranchers.
The traditional answers work only when the economics align. In Schramm's experience, a 29-acre brushy pasture is too small for a half-million-dollar ground rig to bother with. A helicopter can cover hundreds of acres an hour but won't spray precisely over a dense thicket. And shredding with a tractor makes things worse: it stresses the plants, accelerates regrowth, and leaves fields full of stumps that prevent other equipment from entering afterward.
"A lot of my work is a fix to poor management practices from decades, even lifetimes of ranchers and landowners mismanaging property," says Schramm, "Letting native brush and other invasive species come in and take over."
A Different Kind of Precision
Brush work comes with a different set of demands than open-field spraying. Schramm's jobs involve dense, irregularly shaped thickets, damaged terrain, and pastures laced with electrical lines. Although agricultural spray drones are built to handle a range of priorities, he knows that penetration and precision matter most for his work. "What good would a wide swath do me if it didn't have the force to push the chemical all the way down through the canopy?" he says.
He chose the XAG P150, starting operations in August 2025. The quad-rotor design generates a strong, concentrated downdraft, and paired with the RevoSpray System, it reaches a maximum flow rate of 7.9 gallons per minute (30 liters per minute), pushing herbicide uniformly through canopy layers to the understory below. When Schramm hovers over a dense mesquite stand, landowners expect the spray to drift down gently, like rain under a tree. What they see instead surprises them every time. "When the drone goes over, the plants swirl, the ground's blowing up in the dust, and the chemical reaches every bit of the plant, not just the soil. They're always impressed."
The drone's 4D imaging radar detects obstacles between 5 and 328 feet along the flight path (1.5 to 100 meters), enabling safe operation across the uneven, obstacle-heavy terrain Schramm navigates daily. Real-time 3D terrain mapping enables autonomous flight without a preloaded map, adjusting continuously to each new field's contours. "The way it quickly adjusts... it makes me laugh every time," he says. "That's incredible to me, because I'm thinking about all that math that has to compute to know what the speed, height, and all those variables to make a decision in a millisecond."
The P150's foldable design also lets Schramm load, launch, and manage a full day's operation alone. For a small-business owner in his first years of operation, working solo means lower overhead and more profit. It's also a practical necessity: his jobs are often on properties where larger equipment simply can't reach.
The results have been clear. His first job, a shredder-damaged pasture of mixed mesquite, prickly pear, and huisache, looked one month later like a war zone. "It killed everything but the grass," Schramm says, recalling the landowner calling him out to come see it.
In his first season, August through December 2025, he completed 682 acres of brushwork without losing a single client. For each of those ranchers, recovered pasture means more grass, more cattle weight, and more income — a chain of returns that begins with getting the brush out.
Land, Cattle, and Family
Schramm didn't arrive here through a straight line. He spent decades connected to the land, first through his family's poultry operation for Tyson Foods from 1977 to 2015, and before that through his grandfather, a county conservation resource manager for 31 years who taught young Curtis to identify grasses, understand invasive plants, and know when and how to treat them. "All those techniques I grew up learning turned out to be something I needed when I was in my late 40s and early 50s," he laughs. "Here I am doing this."
For Schramm, the work has always been about more than brush. "If you're in a drought, you need to feed your cattle as cheaply as possible," he says. "The quicker you can put weight on, the more money you can make." He's brought his refill cycle down to under 32 seconds: batteries swapped, tank refilled, drone back in the air in under a minute, because every minute on the ground is a minute not serving that chain. "The idea is to feed your land to feed your cattle to feed your family."
"It's my life now," he says. "When I wake up at 4 in the morning to go somewhere and do something with the drone, I'm super excited. It's been something that's filled my life, and for my family, very well."
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
For Texas Ranchers Fighting Invasive Brush, XAG Drones Are Changing the Odds
For Texas Ranchers Fighting Invasive Brush, XAG Drones Are Changing the Odds
|
PERTH, Australia, March 17, 2026 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry, Manufacturing, and Controls) program for the advancement of RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care settings.
A reformulated RLS-2201 is being produced at BioCina's sterile manufacturing facility in Perth, under conditions designed to confirm the reproducibility and robustness of the manufacturing process. The reformulated RLS-2201 will support ICH-aligned stability studies required for regulatory submission and provide early supply for Patrys' planned first-in-human clinical activities.
"We are proud to be advancing RLS-2201 alongside a world-class CDMO partner whose deep manufacturing expertise and technical capabilities are proving instrumental in de-risking this program. Their collaborative approach to regulatory engagement gives us strong confidence as we move toward clinical trials. Together, we believe RLS-2201 has the potential to address a critical unmet need in the treatment of delirium in acute hospital settings," said Dr. Samantha South, CEO, Patrys.
The initiation of CMC activities represents a significant de-risking step for the RLS-2201 program. By validating the manufacturing process for clinical readiness at this stage, Patrys and BioCina are establishing a technically sound and regulatorily defensible pathway toward clinical trial entry, targeted for the second half of 2026. This engagement further strengthens BioCina's partnership with Patrys, reflecting BioCina's commitment to supporting clients at every stage of their product development journey.
"We are thrilled to support Patrys' journey for RLS-2201. BioCina's 50 years of experience in the development and manufacturing of sterile injectables is more than just a capability. We ensure partners like Patrys can progress to clinic with confidence, and keep the focus where it belongs - improving patient outcomes," said Dr. Tommy Broudy, CEO, BioCina.
About BioCina
BioCina is a global end-to-end Contract Development and Manufacturing Organisation (CDMO) with over 50 years of sterile Drug Product manufacturing experience, serving clients across the U.S., Europe, and Asia Pacific. With facilities recognised by the US FDA, EMA, TGA, and other key regulatory authorities, BioCina delivers Drug Substance and Drug Product solutions from early development through to commercial scale.
BioCina's capabilities span sterile injectable manufacturing of small and large molecule products in multiple formats, as well as microbial biologics, pDNA, mRNA and LNP-based modalities. Partnering with BioCina in Australia provides clients with access to one of the world's most attractive R&D tax incentive programs, offering a meaningful cost advantage throughout development and manufacture.
For more information, visit www.biocina.com
About Patrys
Based in Perth, Australia, Patrys, (ASX: PAB), is a clinical-stage biotechnology company advancing a dual-platform strategy combining innovative antibody therapeutics with a near-term CNS pharmaceutical program. Patrys' deoxymab platform comprises novel cell-penetrating antibodies targeting intracellular disease mechanisms with a focus on immune-mediated inflammatory and other high-unmet-need indications.
Patrys' CNS program, RLS-2201, is a proprietary injectable reformulation of quetiapine for the treatment of delirium in intensive, aged and palliative care setting, advancing via the FDA 505(b)(2) regulatory pathway. Together, these platforms position Patrys as a catalyst-rich, balanced development company, combining a de-risked reformulation asset with longer-term biologics innovation.
For more information, visit www.patrys.com
Media Contact
media@biocina.com
Photo - https://mma.prnasia.com/media2/2933870/patrys_release_image_250225_8335.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2346937/BioCina_New_Logo.jpg?p=medium600
PERTH, Australia, March 17, 2026 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry, Manufacturing, and Controls) program for the advancement of RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care settings.
A reformulated RLS-2201 is being produced at BioCina's sterile manufacturing facility in Perth, under conditions designed to confirm the reproducibility and robustness of the manufacturing process. The reformulated RLS-2201 will support ICH-aligned stability studies required for regulatory submission and provide early supply for Patrys' planned first-in-human clinical activities.
"We are proud to be advancing RLS-2201 alongside a world-class CDMO partner whose deep manufacturing expertise and technical capabilities are proving instrumental in de-risking this program. Their collaborative approach to regulatory engagement gives us strong confidence as we move toward clinical trials. Together, we believe RLS-2201 has the potential to address a critical unmet need in the treatment of delirium in acute hospital settings," said Dr. Samantha South, CEO, Patrys.
The initiation of CMC activities represents a significant de-risking step for the RLS-2201 program. By validating the manufacturing process for clinical readiness at this stage, Patrys and BioCina are establishing a technically sound and regulatorily defensible pathway toward clinical trial entry, targeted for the second half of 2026. This engagement further strengthens BioCina's partnership with Patrys, reflecting BioCina's commitment to supporting clients at every stage of their product development journey.
"We are thrilled to support Patrys' journey for RLS-2201. BioCina's 50 years of experience in the development and manufacturing of sterile injectables is more than just a capability. We ensure partners like Patrys can progress to clinic with confidence, and keep the focus where it belongs - improving patient outcomes," said Dr. Tommy Broudy, CEO, BioCina.
About BioCina
BioCina is a global end-to-end Contract Development and Manufacturing Organisation (CDMO) with over 50 years of sterile Drug Product manufacturing experience, serving clients across the U.S., Europe, and Asia Pacific. With facilities recognised by the US FDA, EMA, TGA, and other key regulatory authorities, BioCina delivers Drug Substance and Drug Product solutions from early development through to commercial scale.
BioCina's capabilities span sterile injectable manufacturing of small and large molecule products in multiple formats, as well as microbial biologics, pDNA, mRNA and LNP-based modalities. Partnering with BioCina in Australia provides clients with access to one of the world's most attractive R&D tax incentive programs, offering a meaningful cost advantage throughout development and manufacture.
For more information, visit www.biocina.com
About Patrys
Based in Perth, Australia, Patrys, (ASX: PAB), is a clinical-stage biotechnology company advancing a dual-platform strategy combining innovative antibody therapeutics with a near-term CNS pharmaceutical program. Patrys' deoxymab platform comprises novel cell-penetrating antibodies targeting intracellular disease mechanisms with a focus on immune-mediated inflammatory and other high-unmet-need indications.
Patrys' CNS program, RLS-2201, is a proprietary injectable reformulation of quetiapine for the treatment of delirium in intensive, aged and palliative care setting, advancing via the FDA 505(b)(2) regulatory pathway. Together, these platforms position Patrys as a catalyst-rich, balanced development company, combining a de-risked reformulation asset with longer-term biologics innovation.
For more information, visit www.patrys.com
Media Contact
media@biocina.com
Photo - https://mma.prnasia.com/media2/2933870/patrys_release_image_250225_8335.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2346937/BioCina_New_Logo.jpg?p=medium600
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
BioCina Initiates Comprehensive Manufacturing Program for Patrys' Proprietary Injectable Therapeutic to Alleviate Delirium
